Navigation Links
Cancer vaccine could use immune system to fight tumors
Date:2/27/2014

CINCINNATICincinnati Cancer Center (CCC) and UC Cancer Institute researchers have found that a vaccine, targeting tumors that produce a certain protein and receptor responsible for communication between cells and the body's immune system, could initiate the immune response to fight cancer.

These findings, published in the Feb. 27 online edition of the journal Gene Therapy, build on previously reported research and could lead to new treatments for cancer.

Principal Investigator John Morris, MD, clinical co-leader of the Molecular Therapeutics and Diagnosis Program for the CCC, co-leader of the UC Cancer Institute's Comprehensive Lung Cancer Program, professor in the division of hematology oncology at the UC College of Medicine and UC Health medical oncologist, says a number of antitumor vaccines have shown promise for causing immune responses against tumor antigens to improve patient outcomes.

"Recently, human Interleukin-15 (IL-15) has entered clinical trials for treatment of patients with melanoma, a type of skin cancer, and renal cancer. In this study, we examined the effectiveness of a vaccination targeting tumors that produced IL-15 and its cell surface receptor called IL-15R-alpha () and examined their ability to up-regulate (or increase) immune responses to tumor antigens," Morris says. "We showed that the presence of both IL-15 with its receptor IL-15Rα increased the cell-surface production and secretion of IL-15, and in turn, stopped tumor cells from reproducing."

Researchers used IL-15 to develop a whole tumor cell vaccine to target breast (TS/A) and prostate (TRAMP-C2) cancer cells in animal models; results showed that tumor cells stopped growing after the vaccine was introduced and that beneficial effects were enhanced further when IL-15Rα was co-produced by the vaccine cells.

Morris says vaccination with modified tumor cells producing IL-15 and IL-15Rα slowed tumor growth and led to increased survival for animal models. Furthermore, the cells that control the immune responses (CD8+ T-cells and NK cells) were elevated in these tumors, showing evidence of a true immune response.

"IL-15 is a powerful pro-inflammatory protein that can enhance immune responses," he says. "Our findings suggest that genetically altering tumor cells to produce IL-15 and IL-15Rα can cause and enhance immune responses to tumor antigens found in these tumor cells and can be used as a vaccine to target these antigens.

"Additionally, this provides evidence needed to begin investigating a vaccine in human cancer clinical trials to determine whether genetically modified tumor cells producing IL-15 and IL-15Rα may induce anti-cancer responses."


'/>"/>
Contact: Katie Pence
katie.pence@uc.edu
513-558-4561
University of Cincinnati Academic Health Center
Source:Eurekalert

Related medicine news :

1. More intensive radiotherapy is better than less for localized prostate cancer
2. Skin cancer risk may have driven evolution of black skin
3. Penn researchers show nuclear stiffness keeps stem cells and cancer cells in place
4. CWRU researchers find byproducts of bacteria-causing gum disease incite oral cancer growth
5. Building a better mouse model to understand pancreatic cancer
6. The only top 10 cancer where survival rates are falling
7. A paper diagnostic for cancer
8. Uninsured adolescents and young adults more likely to be diagnosed with advanced cancer
9. Dismantling pancreas cancers armor
10. Feasible, safe to limit radiation to major salivary glands in head and neck cancer patients
11. Patients with oropharyngeal cancer report quality of voice and speech affected post-treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... , ... December 06, 2016 ... ... on Friday, November 25th, when SevenPoint2 released the much-anticipated HydroFX for Water®. ... eye-catching label design. Featuring one of the world’s most powerful antioxidants, molecular ...
(Date:12/6/2016)... ... December 06, 2016 , ... TopConsumerReviews.com recently gave a ... Scooters . , Mobility Scooters give freedom to people who need help getting around. ... may be facing a long period of rehabilitation after an illness or accident. There ...
(Date:12/5/2016)... ... December 05, 2016 , ... "FCPX Overlay Glare is a ... lighting effect without heavy rendering or complicated compositing," said Christina Austin - CEO of ... create an organic spectrum of lights that simulates the look of a glare. ...
(Date:12/5/2016)... GA (PRWEB) , ... December ... ... technology and security executive networking and relationship-marketing firm, announced today that nominations ... the 2017 Information Security Executive® (ISE®) Central Awards. , Awards include the ...
(Date:12/5/2016)... ... December 05, 2016 , ... Physicians Education ... Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma, on ... “We are honored to have Amy E. Herman present at this year’s conference, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec. 5, 2016   Lexicon Pharmaceuticals, ... results today from a Phase 2 clinical study of ... Lexicon in collaboration with JDRF, the leading global organization ... of this Phase 2 clinical trial, which randomized a ... of a once-daily 400 mg dose of sotagliflozin compared ...
(Date:12/5/2016)... , December 5, 2016 According to ... Treatment modalities (Chondrocyte Transplantation, Growth Factor Technology, Tissue Scaffolds, Cell-free composites), ... by MarketsandMarkets, the market is projected to reach USD 779.8 Million ... CAGR of 13.5% during the forecast period of 2016 to 2021. ... ...
(Date:12/5/2016)... PORTLAND, Oregon and PUNE, India ... a new report by Allied Market Research, titled, "Global Cancer ... the global revenue of cancer biomarkers market is projected to ... at a CAGR of 13.3% from 2016 to 2022. Omic ... share in 2015 and is expected to maintain its dominance ...
Breaking Medicine Technology: